Satsuma
Selected indexed studies
- Interstitial lung disease: a review of classification, etiology, epidemiology, clinical diagnosis, pharmacological and non-pharmacological treatment. (Front Med (Lausanne), 2024) [PMID:38698783]
- Advances in migraine prevention. (Lancet Neurol, 2026) [PMID:41722594]
- Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. (Lancet, 2023) [PMID:37516125]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. (2023) pubmed
- Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis. (2024) pubmed
- Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA. (2023) pubmed
- Interstitial lung disease: a review of classification, etiology, epidemiology, clinical diagnosis, pharmacological and non-pharmacological treatment. (2024) pubmed
- Advances in migraine prevention. (2026) pubmed
- β-Cryptoxanthin from Satsuma Mandarin and Its Multiple Functions. (2021) pubmed
- Response. (2026) pubmed
- Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial. (2024) pubmed
- Fruit photosynthesis in Satsuma mandarin. (2015) pubmed
- Molecular characterization of Satsuma mandarin (Citrus unshiu Marc.) VASCULAR PLANT ONE-ZINC FINGER2 (CuVOZ2) interacting with CuFT1 and CuFT3. (2023) pubmed